Positive results for zoliflodacin, EMA approval for fexinidazole and Merck cuts rotavirus commitment – take a look a the month’s industry headlines.
Browsing: Drug Development
Researchers from the University of Zurich have discovered that thanatin, a compound produced naturally by the spined soldier bug, could target Gram-negative bacteria by preventing formation of the bacteria’s outer membrane – an unprecedented mechanism.
Overcoming intrinsic resistance in Pseudomonas aeruginosa using non-ribosome targeting tobramycin-based adjuvants
In this article, the authors discuss their research using non-ribosome targeting tobramycin-based adjuvants to overcome the intrinsic resistance observed in bacteria, Pseudomonas aeruginosa.
In recent years, researchers have discovered the potential of CRISPR as an antimicrobial. In this blog post we explain the recent advances made in this field and the different approaches by which CRISPR can be used as a new weapon in the battle against antimicrobial resistance.
A Phase II trial has demonstrated that a new investigational antibiotic, cefiderocol, is as effective as the current standard-of-care for treating complicated UTIs caused by multi-drug resistant bacteria.
Roche has announced the FDA approval of Xofluza™, the first and only single-dose oral medicine approved to treat flu.
Small molecules that block bacterial toxin formation have shown promise against Gram-positive bacteria in mouse models.
In this interview, we speak to to Keith Kaye, Principle Investigator of the RESTORE-1 trial assessing relebactam in combination with imipenem (IMI/REL), about the trial’s results and the implications these have for clinicians in ‘real world’ settings.
A Phase III study, TANGO II, has reported that meropenem–vaborbactam monotherapy for CRE infections was associated with improvement in clinical cure rates, lower nephrotoxicity and lower mortality versus best-available therapy.
GARDP and Novartis have announced a partnership hoping to accelerate the development and availability of generic antibiotics for children in LMICs.